 Peter Hountras
Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Embolism | 3 | 2021 | 222 | 1.300 |
Why?
| | Thrombectomy | 2 | 2020 | 64 | 0.830 |
Why?
| | Cardiac Output, High | 1 | 2022 | 1 | 0.760 |
Why?
| | Chest Pain | 2 | 2020 | 91 | 0.760 |
Why?
| | POEMS Syndrome | 1 | 2022 | 3 | 0.760 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2022 | 6 | 0.760 |
Why?
| | Telangiectasia, Hereditary Hemorrhagic | 1 | 2022 | 13 | 0.750 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 2022 | 24 | 0.750 |
Why?
| | Arteriovenous Malformations | 1 | 2022 | 27 | 0.740 |
Why?
| | Thrombolytic Therapy | 2 | 2021 | 145 | 0.670 |
Why?
| | Antiphospholipid Syndrome | 1 | 2020 | 38 | 0.670 |
Why?
| | Heart Atria | 1 | 2020 | 136 | 0.650 |
Why?
| | Hemoptysis | 1 | 2019 | 35 | 0.610 |
Why?
| | Pulmonary Edema | 1 | 2019 | 106 | 0.600 |
Why?
| | Cough | 1 | 2019 | 121 | 0.580 |
Why?
| | Fibrinolytic Agents | 1 | 2020 | 271 | 0.560 |
Why?
| | Coccidioidomycosis | 1 | 2017 | 7 | 0.560 |
Why?
| | Lung Diseases, Fungal | 1 | 2017 | 13 | 0.560 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2020 | 290 | 0.530 |
Why?
| | Thrombosis | 1 | 2020 | 368 | 0.530 |
Why?
| | Respiratory Sounds | 1 | 2017 | 123 | 0.520 |
Why?
| | Anticoagulants | 2 | 2021 | 662 | 0.520 |
Why?
| | Pulmonary Alveoli | 1 | 2019 | 405 | 0.510 |
Why?
| | Seizures | 1 | 2019 | 427 | 0.480 |
Why?
| | Respiratory Insufficiency | 1 | 2017 | 316 | 0.430 |
Why?
| | Pneumonia, Bacterial | 3 | 2019 | 117 | 0.410 |
Why?
| | Liver | 1 | 2022 | 1937 | 0.410 |
Why?
| | Hypoxia | 1 | 2019 | 1106 | 0.370 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1901 | 0.330 |
Why?
| | Vena Cava Filters | 2 | 2020 | 61 | 0.320 |
Why?
| | Heart Failure | 1 | 2022 | 2210 | 0.290 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2019 | 53 | 0.280 |
Why?
| | Acute Disease | 2 | 2020 | 1000 | 0.250 |
Why?
| | Respiration, Artificial | 3 | 2019 | 643 | 0.240 |
Why?
| | Critical Care | 2 | 2017 | 583 | 0.190 |
Why?
| | Tadalafil | 1 | 2022 | 7 | 0.190 |
Why?
| | Telangiectasis | 1 | 2022 | 7 | 0.190 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2022 | 40 | 0.190 |
Why?
| | Hepatic Veins | 1 | 2022 | 33 | 0.190 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2022 | 37 | 0.190 |
Why?
| | Hepatic Artery | 1 | 2022 | 61 | 0.190 |
Why?
| | Syncope | 1 | 2022 | 52 | 0.180 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2022 | 44 | 0.180 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2022 | 98 | 0.180 |
Why?
| | Edema | 1 | 2022 | 129 | 0.180 |
Why?
| | Endarterectomy | 1 | 2020 | 6 | 0.180 |
Why?
| | Conversion to Open Surgery | 1 | 2020 | 16 | 0.170 |
Why?
| | Radiography, Thoracic | 1 | 2022 | 168 | 0.170 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 129 | 0.170 |
Why?
| | Embolectomy | 1 | 2020 | 13 | 0.170 |
Why?
| | Portal Vein | 1 | 2022 | 117 | 0.170 |
Why?
| | Stem Cell Transplantation | 1 | 2022 | 177 | 0.170 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 80 | 0.170 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 310 | 0.160 |
Why?
| | Exercise Tolerance | 1 | 2022 | 277 | 0.160 |
Why?
| | Dexamethasone | 1 | 2022 | 374 | 0.160 |
Why?
| | Dyspnea | 1 | 2020 | 251 | 0.150 |
Why?
| | Echocardiography | 1 | 2022 | 659 | 0.150 |
Why?
| | Cardiac Catheterization | 1 | 2022 | 528 | 0.150 |
Why?
| | Tomography, X-Ray Computed | 2 | 2019 | 2670 | 0.140 |
Why?
| | Metagenomics | 1 | 2019 | 167 | 0.140 |
Why?
| | Pseudomonas Infections | 1 | 2019 | 224 | 0.130 |
Why?
| | Pulmonary Medicine | 1 | 2017 | 83 | 0.130 |
Why?
| | Humans | 14 | 2022 | 136899 | 0.130 |
Why?
| | Pseudomonas aeruginosa | 1 | 2019 | 353 | 0.130 |
Why?
| | Weight Loss | 1 | 2022 | 765 | 0.130 |
Why?
| | Endovascular Procedures | 1 | 2020 | 310 | 0.130 |
Why?
| | Macrophages, Alveolar | 1 | 2019 | 392 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 367 | 0.120 |
Why?
| | Middle Aged | 5 | 2022 | 33118 | 0.120 |
Why?
| | Biopsy | 1 | 2019 | 1130 | 0.120 |
Why?
| | Patient Care Team | 1 | 2020 | 624 | 0.120 |
Why?
| | Cross Infection | 1 | 2017 | 238 | 0.110 |
Why?
| | Female | 8 | 2022 | 72703 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1484 | 0.110 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 941 | 0.100 |
Why?
| | Societies, Medical | 1 | 2017 | 816 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1689 | 0.100 |
Why?
| | Bacteria | 1 | 2019 | 855 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1575 | 0.100 |
Why?
| | Curriculum | 1 | 2017 | 978 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2021 | 10768 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 763 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1790 | 0.080 |
Why?
| | Aged | 3 | 2022 | 23641 | 0.070 |
Why?
| | Lung | 1 | 2017 | 4046 | 0.050 |
Why?
| | Adult | 4 | 2020 | 37595 | 0.050 |
Why?
| | Male | 5 | 2022 | 67308 | 0.050 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 23 | 0.050 |
Why?
| | Catheters | 1 | 2021 | 72 | 0.040 |
Why?
| | Vascular Resistance | 1 | 2021 | 372 | 0.040 |
Why?
| | Heparin | 1 | 2021 | 259 | 0.040 |
Why?
| | Dental Plaque | 1 | 2017 | 18 | 0.030 |
Why?
| | Probiotics | 1 | 2017 | 52 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2019 | 654 | 0.030 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 126 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1684 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2021 | 15514 | 0.020 |
Why?
| | Achievement | 1 | 1970 | 61 | 0.020 |
Why?
| | Gastrointestinal Microbiome | 1 | 2017 | 689 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4281 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5711 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 7552 | 0.020 |
Why?
| | Students | 1 | 1970 | 625 | 0.010 |
Why?
| | Anxiety | 1 | 1970 | 1039 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 13157 | 0.010 |
Why?
| | United States | 2 | 2017 | 14595 | 0.010 |
Why?
| | Mice | 1 | 2019 | 17775 | 0.010 |
Why?
| | Animals | 1 | 2019 | 36915 | 0.010 |
Why?
| | Social Desirability | 1 | 1970 | 15 | 0.010 |
Why?
| | Psychological Tests | 1 | 1970 | 139 | 0.010 |
Why?
| | Canada | 1 | 1970 | 417 | 0.000 |
Why?
| | Universities | 1 | 1970 | 431 | 0.000 |
Why?
|
|
Hountras's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|